A Aralex Aachen research explorer

Rémi Veillon Sign in to save

ORCID 0009-0000-3336-3922 OpenAlex profile details not fetched

–

Citations

–

h-index

–

i10-index

–

Works (all)

0

Aachen papers

Departments & institutes in Aachen

No department could be parsed from this author's affiliation strings.

Affiliations exactly as printed on papers (1)

4× CHU Bordeaux, service des maladies respiratoires, Bordeaux, France

Papers 4 stored

All · Aachen affiliation only

PP01.28: Treatment Sequencing of Tepotinib in Patients With MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC): Outcomes From ≥3 Years Follow-Up of the VISION Study
2026 Journal of Thoracic Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations

0

citations
PP01.27: Tepotinib in Patients with MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC) From the VISION Study: ≥3-Year Follow-Up Outcomes
2026 Journal of Thoracic Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations

0

citations
PP01.23: Safety and Patient-Reported Outcomes with Tepotinib in Patients with METex14 Skipping NSCLC: ≥3-Years Follow-Up of VISION
2026 Journal of Thoracic Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations

0

citations
PP01.29: Long-Term Outcomes with Tepotinib for Clinically Relevant Subgroups of Patients with MET Exon 14 (METex14) Skipping NSCLC in the VISION Study: A ≥3-Year Follow-Up
2026 Journal of Thoracic Oncology conference-abstract Medicine Lung Cancer Treatments and Mutations

0

citations

4 results